| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPRB |
| Uniprot No | P23467 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1643-1997aa |
| 氨基酸序列 | RQKVSHGRERPSARLSIRRDRPLSVHLNLGQKGNRKTSCPIKINQFEGHFMKLQADSNYLLSKEYEELKDVGRNQSCDIALLPENRGKNRYNNILPYDATRVKLSNVDDDPCSDYINASYIPGNNFRREYIVTQGPLPGTKDDFWKMVWEQNVHNIVMVTQCVEKGRVKCDHYWPADQDSLYYGDLILQMLSESVLPEWTIREFKICGEEQLDAHRLIRHFHYTVWPDHGVPETTQSLIQFVRTVRDYINRSPGAGPTVVHCSAGVGRTGTFIALDRILQQLDSKDSVDIYGAVHDLRLHRVHMVQTECQYVYLHQCVRDVLRARKLRSEQENPLFPIYENVNPEYHRDPVYSRH |
| 预测分子量 | 43.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTPRB重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *"Recombinant extracellular domain of protein tyrosine phosphatase receptor type B (PTPRB) suppresses angiogenesis by blocking VEGF signaling"*
**作者**: Hayashi M, et al.
**摘要**: 研究利用重组表达的PTPRB胞外结构域，发现其可通过竞争性结合VEGF(血管内皮生长因子)抑制血管内皮细胞增殖和迁移，提示其在抗血管生成治疗中的潜在应用。
2. **文献名称**: *"Structural and functional analysis of the protein tyrosine phosphatase PTPRB catalytic domain"*
**作者**: Barr AJ, et al.
**摘要**: 通过重组表达PTPRB的催化结构域，解析其晶体结构并验证其磷酸酶活性，揭示了底物结合的关键氨基酸残基，为设计靶向抑制剂提供了结构基础。
3. **文献名称**: *"PTPRB regulates endothelial cell motility through dephosphorylation of VE-cadherin complex proteins"*
**作者**: Sui Z, et al.
**摘要**: 利用重组PTPRB蛋白进行体外磷酸化实验，证明其通过去磷酸化VE-钙黏蛋白复合物调控内皮细胞连接稳定性，影响血管通透性和细胞迁移。
---
以上文献均涉及重组PTPRB蛋白的表达与功能研究，涵盖抗血管生成、结构解析及细胞信号调控等方向。
**Background of PTPRB Recombinant Protein**
Protein tyrosine phosphatase receptor type B (PTPRB), also known as vascular endothelial protein tyrosine phosphatase (VE-PTP), is a transmembrane enzyme belonging to the protein tyrosine phosphatase (PTP) family. It plays a critical role in regulating cellular signaling pathways by dephosphorylating tyrosine residues on target proteins, thereby modulating processes such as cell adhesion, migration, and vascular development. PTPRB is particularly notable for its involvement in maintaining vascular integrity and angiogenesis. It interacts with key endothelial receptors, including Tie-2 and vascular endothelial (VE)-cadherin, to stabilize cell-cell junctions and control vascular permeability. Dysregulation of PTPRB has been linked to pathological conditions, including cancer metastasis, inflammatory diseases, and abnormal blood vessel formation.
Recombinant PTPRB protein is engineered *in vitro* using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional forms of the enzyme or its domains (e.g., the extracellular or catalytic segments). This allows researchers to study its structure, enzymatic activity, and interactions in controlled settings. The recombinant protein often retains critical functional regions, such as the catalytic phosphatase domain, enabling investigations into substrate specificity and inhibition mechanisms.
Studies leveraging PTPRB recombinant protein have advanced drug discovery, particularly in targeting angiogenesis-related diseases. Inhibitors or modulators of PTPRB activity are explored for therapeutic potential in cancer and vascular disorders. Additionally, the protein serves as a tool for elucidating signaling pathways in endothelial cells, contributing to our understanding of cardiovascular biology and tissue homeostasis.
(Word count: 248)
×
